About Platinum OG

Platinum OG is known as a heavy hitter, bred by Mendocino Farms to be just that. They combined Master Kush and OG Kush into a strain that’s anything but delicate.

American Bred

Platinum OG wears its luxury on its sleeve. THC levels for Platinum OG range from 20% to 24%. It also retains 1% CBD and 1% CBN.

Platinum OG is known as a heavy hitter, bred by Mendocino Farms to be just that. They combined Master Kush and OG Kush into a strain that’s anything but delicate. Some researchers suspect that there’s some Mendocino Purps in there as well.

The strain has the distinct taste of pine nuts, as well as overtones of diesel, the smell of spice, and even a taste of coffee. The combination produces herbal, earthy sensations – none of the froufrou fruity flavours of some of these other strains.

Platinum OG grows best outside, particularly in sunny, warm climates, and flowers in 63 days, give or take. The strain’s hardiness makes it resistant to diseases, mould, and mildew, which makes it friendlier for novice growers, especially those in humid climates. The plant itself develops into a shade of light silver-platinum beneath a coat of resin and crystals, concealing purple tones and orange hairs.

Description provided by Wikileaf.

Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).

About Lyphe Group Ltd

From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.

At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.

lyphegroup.com